|

New G8 Screening Questionnaire for Mesothelioma Treatments

ByHolly Zink
New G8 Screening Questionnaire for Mesothelioma Treatments

A screening questionnaire for lung cancer patients could improve treatment plans and clinical outcomes.

This is the conclusion of a team of researchers from the United Kingdom.

Mesothelioma is a rare type of cancer that often forms in the lungs of affected patients. It is caused by exposure to asbestos, usually in the work environment. It takes a long time for mesothelioma symptoms for appear. Because of this, most mesothelioma patients are elderly.

Introducing the G8 Questionnaire

The G8 questionnaire is a geriatric screening tool for doctors to use when choosing treatment options for patients with cancer. It takes up to five minutes for a doctor to complete the questionnaire. It includes eight questions and provides a score between zero and 17.

A G8 score of 14 or higher is considered “normal”. A score of 13 or lower is considered “abnormal”. Higher scores mean a patient is healthy enough to receive more intensive treatment. Lower scores mean a patient may be too frail for intensive treatment.

The results of the G8 questionnaire could help a doctor make better treatment decisions with their patient. The authors of this study investigated treatment decisions and outcomes from 201 patients. They wanted to find out if the G8 questionnaire led to treatments that improved survival.

The patients in this study had non-small cell lung cancer, small cell lung cancer, or mesothelioma.

Does Well Does it Work?

About 10% of patients’ treatment plans were changed after their doctors used the G8 questionnaire. Patients with high G8 scores received higher chemotherapy intensity than patients with intermediate or low G8 scores.

Patients with normal G8 scores survived about six months longer than patients with abnormal G8 scores.

The results of this study show that the G8 questionnaire can be a helpful tool for doctors treating patients with mesothelioma. They can use it to design more effective treatment plans for their patients. This is important for an aggressive cancer like mesothelioma.

Source

Wu X, Kumar R, Milner-Watts C, et al. The Predictive Value of the G8 Questionnaire in Older Patients with Lung Cancer or Mesothelioma before Systemic Treatment [published online ahead of print, 2022 Nov 17]. Clin Oncol (R Coll Radiol). 2022;S0936-6555(22)00515-5. doi:10.1016/j.clon.2022.10.020

Similar Posts

  • | |

    Doctors Describe "Concrete Therapeutic Approach" for Mesothelioma

    ByAlex Strauss

    A team of medical researchers in Italy have achieved what they are calling “excellent” tumor control and survival results in malignant pleural mesothelioma patients using a combination of surgery, chemotherapy, and radiotherapy. Caused by exposure to asbestos, mesothelioma typically spreads quickly across the lung-encasing membrane called the pleura. There is no known cure but treatments are improving. In the current prospective study, 20 malignant pleural mesothelioma patients underwent radical pleurectomy/decortication followed by high doses of radiation. After surgeons removed as much of the visible mesothelioma tumor and surrounding tissue as possible, patients received 50Gy of radiation to the effected side of their chest, delivered in 25 fractions. Regions of particular concern for mesothelioma regrowth got an extra radiation “boost” to…

  • | |

    Does Radiotherapy Reduce Mesothelioma Pain?

    ByAlex Strauss

    A new study says there is not enough evidence to support the use of radiotherapy for the treatment of pain associated with malignant pleural mesothelioma. Researchers at the University of Edinburgh in Scotland reviewed a range of past studies on mesothelioma pain and radiotherapy by searching databases that date back as far as 1974. To be eligible to be included in their review, the study had to focus on malignant pleural mesothelioma and radiotherapy given “with the intent of improving pain”. The study also had to report doses and fractionation of the radiotherapy and how the pain responded. In all, the researchers found eight studies on mesothelioma pain and radiotherapy that met the criteria. Two of the studies were prospective…

  • | |

    Radiotherapy for Mesothelioma: Better But Still Limited

    ByAlex Strauss

    A form of highly-targeted radiation therapy for mesothelioma is better than it used to be, but is still risky. That is the message of a recent article on intensity-modulated radiation therapy (IMRT) in Seminars in Thoracic and Cardiovascular Surgery. Author Kenneth E. Rosenzweig, MD, a Radiation Oncologist with Mount Sinai Hospital in New York, reviewed recent studies on IMRT and mesothelioma. He concludes that, while the “troubling toxicity” associated with IMRT when it was first introduced has not been entirely eliminated, the fact that clinicians now have more experience with it is making a positive difference for mesothelioma patients. Before targeted therapies like IMRT were available, high-dose radiation was not usually a feasible option for mesothelioma since the irregular shape…

  • | |

    A Second-Line Option for Mesothelioma?

    ByAlex Strauss

    Although survival was not significantly extended, the chemotherapy drug vinorelbine might be a treatment option for mesothelioma patients whose cancer has returned after first-line chemotherapy with pemetrexed. A new study on vinorelbine as a second-line treatment finds that the drug is “moderately active” in mesothelioma patients who were initially treated with pemetrexed-based chemotherapy. Pemetrexed (Alimta), along with a platinum-based drug like cisplatin, is the primary first-line drug therapy for mesothelioma. But vinorelbine is gaining attention as a possible option for mesothelioma, in part because it is available in a less expensive generic form. In “Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma”, the Italian authors detail the results of their study on 59 patients with unresectable pleural mesothelioma.  These patients…

  • |

    Mesothelioma Blood Test May Be Possible

    ByAlex Strauss

    An international team of researchers is studying the proteins found on the surface of cancer cells in an effort to improve mesothelioma diagnosis. The team, made up of scientists from the US, Switzerland, Italy and Chile, has just published their findings on a new kind of test to identify protein-derived mesothelioma biomarkers in blood serum. Mesothelioma is an aggressive cancer of the membranes around organs. Because the most common mesothelioma biomarker, mesothelin, is also overproduced by other kinds of cancer cells, it has only limited diagnostic value. A test to identify a set of proteins produced specifically by mesothelioma cells could greatly improve diagnostic accuracy. Led by Ferdinando Cerciello and Bernd Wollscheid of the Institute of Molecular Systems Biology in…

  • | |

    Repeat HIPEC Improves Mesothelioma Survival

    ByAlex Strauss

    If one cytoreductive surgery and HIPEC procedure for mesothelioma is good, subsequent treatments may be even better. That is the central message of research conducted at the Moffitt Cancer Center in Florida. The study’s aim was to assess overall survival among peritoneal mesothelioma patients who had not just one, but two or more rounds of heated intraperitoneal chemotherapy (HIPEC) after cytoreductive surgery. The cytoreduction/HIPEC approach has become popular for peritoneal mesothelioma, a treatment-resistant cancer of abdominal membranes caused by asbestos. Cytoreductive surgery involves removing as much of the mesothelioma tumor as possible from the abdomen. Because the shape and spreading pattern of mesothelioma tumors make complete cytoreduction difficult, the surgery is often followed by a rinse with a heated solution…